Malley Thomas 4

What Happened

• Malley Thomas, a director of Kiniksa Pharmaceuticals International plc (KNSA), received awards of restricted stock units (RSUs) and had derivative shares converted/settled on May 29, 2026. The filing shows grants of 12,158 RSUs and 2,026 RSUs (total 14,184 RSUs) at $0.00 and a conversion/exercise event involving 2,799 derivative shares. There were no cash proceeds reported for the transactions (all entries show $0.00 or N/A).

Key Details

• Transaction date: May 29, 2026; Form filed June 2, 2026 (filed within the Form 4 two-business-day window).
• Grants: 12,158 RSUs and 2,026 RSUs granted at $0.00 (derivative awards).
• Exercise/conversion: 2,799 derivative shares were converted/issued (acquired) and an equal 2,799 derivative shares were reported disposed at $0.00.
• Shares owned after transaction: Not stated in the supplied summary of the filing.
• Notable footnotes:
  • F1: Each RSU represents a contingent right to one Class A ordinary share.
  • F3–F5: Grant date and vesting terms: the grants date is May 29, 2026; the RSUs vested in a single installment on May 29, 2026 (F5).
  • F2: Mr. Malley is president of Mossrock Capital, LLC and may be deemed to beneficially own shares held by Mossrock.
• Filing timeliness: Report appears timely (filed June 2 for May 29 transactions).

Context

• RSUs are awards that convert into shares when they vest; the $0.00 grant price is standard for awards (not a market purchase). The paired conversion/acquisition and disposal of 2,799 derivative shares typically reflects net settlement or withholding tied to a vesting event rather than an open-market sale (no proceeds were reported). This activity is an award/settlement event, not a discretionary purchase or sale on the open market.